^
Association details:
| Biomarker: | HER-2 R678Q |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | lapatinib (EGFR inhibitor, HER2 inhibitor) + Nerlynx (neratinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Activating HER2 mutations in HER2 gene amplification negative breast cancer
Excerpt:
MCF10A cells transduced with L755S, del.755-759, and R678Q formed fewer colonies than HER2 WT cells. Lapatinib treatment decreased the number of colonies formed in all mutations, except for L755S.
DOI:
10.1158/2159-8290.CD-12-0349
